Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 10/20 | 0.66 |
| ▸ | TEK | Q02763 | 10/20 | 0.66 |
| ▸ | KDR | P35968 | 7/20 | 0.64 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18883533 | 0.85 | TEK (0.60) | EPHB4TEKKDRGSTO1SCN9A | |
| SCHEMBL9953254 | 0.79 | SCN9A (0.78) | SCN9A | |
| SCHEMBL805934 | 0.75 | SCN9A (0.58) | SCN9A | |
| SCHEMBL24168624 | 0.75 | TGM2 (0.61) | KDRTGM2 | |
| SCHEMBL10247654 | 0.74 | SCN9A (0.64) | SCN9A | |
| SCHEMBL15400578 | 0.74 | SCN9A (0.67) | SCN9A | |
| SCHEMBL3139377 | 0.73 | SCN9A (0.72) | SCN9A | |
| SCHEMBL805972 | 0.73 | SCN9A (0.55) | SCN9A | |
| SCHEMBL31745588 | 0.73 | EPHB4 (0.39) | EPHB4TEKKDRGSTO1SCN9A | |
| SCHEMBL174072 | 0.71 | TGM2 (0.53) | EPHB4TEKKDRTGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656959-B2 | Substituted pyridines as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656959-B2 | Substituted pyridines as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2655330-B1 | SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2016-02-10 | — | — | EP | disclosed |
| EP-2655330-B1 | SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2016-02-10 | — | — | EP | disclosed |
| US-20140005212-A1 | Substituted Pyridines as Sodium Channel Blockers | PURDUE PHARMA L.P. (US) | 2014-01-02 | — | — | US | disclosed |
| EP-2655330-A1 | SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS | Purdue Pharma LP (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085650-A1 | SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085650-A1 | SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005212-A1 | Substituted Pyridines as Sodium Channel Blockers | SCN1B, CACNA1A, SCN1A | EPHB4 1058/4885TEK 3023/4885KDR 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.